Blood Kallikrein-8 and Non-Amnestic Mild Cognitive Impairment: An Exploratory Study

Background: Blood kallikrein-8 is supposed to be a biomarker for mild cognitive impairment (MCI) due to Alzheimer’s disease (AD), a precursor of AD dementia. Little is known about the association of kallikrein-8 and non-AD type dementias. Objective: To investigate whether blood kallikrein-8 is elevated in individuals with non-amnestic MCI (naMCI), which has a higher probability to progress to a non-AD type dementia, compared with cognitively unimpaired (CU) controls. Methods: We measured blood kallikrein-8 at ten-year follow-up (T2) in 75 cases and 75 controls matched for age and sex who were participants of the population-based Heinz Nixdorf Recall study (baseline: 2000–2003). Cognitive performance was assessed in a standardized manner at five (T1) and ten-year follow-up. Cases were CU or had subjective cognitive decline (SCD) at T1 and had naMCI at T2. Controls were CU at both follow-ups. The association between kallikrein-8 (per 500 pg/ml increase) and naMCI was estimated using conditional logistic regression: odds ratios (OR) and 95% confidence intervals (95% CI) were determined, adjusted for inter-assay variability and freezing duration. Results: Valid kallikrein-8 values were measured in 121 participants (45% cases, 54.5% women, 70.5±7.1 years). In cases, the mean kallikrein-8 was higher than in controls (922±797 pg/ml versus 884±782 pg/ml). Kallikrein-8 was not associated with having naMCI compared to being CU (adjusted; OR: 1.03 [95% CI: 0.80–1.32]). Conclusion: This is the first population-based study that shows that blood kallikrein-8 tends not to be elevated in individuals with naMCI compared with CU. This adds to the evidence of the possible AD specificity of kallikrein-8.

[1]  S. Shiosaka,et al.  Kallikrein 8: A key sheddase to strengthen and stabilize neural plasticity , 2022, Neuroscience & Biobehavioral Reviews.

[2]  K. Jöckel,et al.  Is kallikrein-8 a blood biomarker for detecting amnestic mild cognitive impairment? Results of the population-based Heinz Nixdorf Recall study , 2021, Alzheimer's Research & Therapy.

[3]  Y. Song,et al.  The association of serum Kallikrein-8 with cognitive function in vascular dementia. , 2021, European review for medical and pharmacological sciences.

[4]  K. Jöckel,et al.  Genetic knockdown of Klk8 has sex‐specific multi‐targeted therapeutic effects on Alzheimer’s pathology in mice , 2020, Neuropathology and applied neurobiology.

[5]  C. Figueroa,et al.  Involvement of Kallikrein-Related Peptidases in Nervous System Disorders , 2020, Frontiers in Cellular Neuroscience.

[6]  Dhiman Ghosh,et al.  Increased plasma bradykinin level is associated with cognitive impairment in Alzheimer's patients , 2020, Neurobiology of Disease.

[7]  2020 Alzheimer's disease facts and figures , 2020, Alzheimer's & dementia : the journal of the Alzheimer's Association.

[8]  K. Keyvani,et al.  Inhibition of excessive kallikrein-8 improves neuroplasticity in Alzheimer's disease mouse model , 2019, Experimental Neurology.

[9]  J. Wiltfang,et al.  CSF and blood Kallikrein-8: a promising early biomarker for Alzheimer’s disease , 2019, Journal of Neurology, Neurosurgery, and Psychiatry.

[10]  S. Moebus,et al.  Subjective cognitive decline, APOE ε4, and incident mild cognitive impairment in men and women , 2019, Alzheimer's & dementia.

[11]  D. Hermann,et al.  Higher levels of kallikrein‐8 in female brain may increase the risk for Alzheimer's disease , 2018, Brain pathology.

[12]  S. Strickland,et al.  A novel detection method of cleaved plasma high-molecular-weight kininogen reveals its correlation with Alzheimer's pathology and cognitive impairment , 2018, Alzheimer's & dementia.

[13]  Y. Mechref,et al.  Implication of the Kallikrein-Kinin system in neurological disorders: Quest for potential biomarkers and mechanisms , 2018, Progress in Neurobiology.

[14]  S. R. Datta,et al.  Filopodia Conduct Target Selection in Cortical Neurons Using Differences in Signal Kinetics of a Single Kinase , 2018, Neuron.

[15]  C. Jack,et al.  NIA-AA Research Framework: Toward a biological definition of Alzheimer’s disease , 2018, Alzheimer's & Dementia.

[16]  C. Ritchie,et al.  CSF tau and the CSF tau/ABeta ratio for the diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI). , 2017, The Cochrane database of systematic reviews.

[17]  T. Arzberger,et al.  Kallikrein-8 Inhibition Attenuates Alzheimer's Pathology in Mice , 2022 .

[18]  M. Greenberg,et al.  EphB receptor forward signaling regulates area-specific reciprocal thalamic and cortical axon pathfinding , 2014, Proceedings of the National Academy of Sciences.

[19]  S. Moebus,et al.  Association of diabetes mellitus and mild cognitive impairment in middle-aged men and women. , 2014, Journal of Alzheimer's disease : JAD.

[20]  M. Thakur,et al.  Neuropsin Expression Correlates with Dendritic Marker MAP2c Level in Different Brain Regions of Aging Mice , 2014, Molecular Neurobiology.

[21]  X. Tong,et al.  Cognitive and cerebrovascular improvements following kinin B1 receptor blockade in Alzheimer’s disease mice , 2013, Journal of Neuroinflammation.

[22]  C. Cowan,et al.  EphB2 receptor forward signaling controls cortical growth cone collapse via Nck and Pak , 2013, Molecular and Cellular Neuroscience.

[23]  Y. Ishikawa,et al.  Processing of Neuregulin-1 by Neuropsin Regulates GABAergic Neuron to Control Neural Plasticity of the Mouse Hippocampus , 2012, The Journal of Neuroscience.

[24]  Raimund Erbel,et al.  Population-Based Distribution and Psychometric Properties of a Short Cognitive Performance Measure in the Population-Based Heinz Nixdorf Recall Study , 2011, Neuroepidemiology.

[25]  Nick C Fox,et al.  The diagnosis of mild cognitive impairment due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.

[26]  K. W. Young,et al.  Neuropsin cleaves EphB2 in the amygdala to control anxiety , 2011, Nature.

[27]  M. Dalva,et al.  EphB Receptors Couple Dendritic Filopodia Motility to Synapse Formation , 2008, Neuron.

[28]  Y. Horii,et al.  Neuropsin (KLK8)-Dependent and -Independent Synaptic Tagging in the Schaffer-Collateral Pathway of Mouse Hippocampus , 2008, The Journal of Neuroscience.

[29]  T. Stief.  Kallikrein Activates Prothrombin , 2008, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

[30]  S. Riedel-Heller,et al.  Mild cognitive impairment , 2006, Neurology.

[31]  T. Kishi,et al.  Activation and enzymatic characterization of recombinant human kallikrein 8 , 2006, Biological chemistry.

[32]  S. Yoshida,et al.  Neuropsin is essential for early processes of memory acquisition and Schaffer collateral long‐term potentiation in adult mouse hippocampus in vivo , 2006, The Journal of physiology.

[33]  S. Moebus,et al.  Baseline recruitment and analyses of nonresponse of the Heinz Nixdorf recall study: Identifiability of phone numbers as the major determinant of response , 2005, European Journal of Epidemiology.

[34]  C. Jack,et al.  Mild cognitive impairment – beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment , 2004, Journal of internal medicine.

[35]  R. Petersen.  Mild cognitive impairment as a diagnostic entity , 2004, Journal of internal medicine.

[36]  T. Tombaugh.  Trail Making Test A and B: normative data stratified by age and education. , 2004, Archives of clinical neuropsychology : the official journal of the National Academy of Neuropsychologists.

[37]  Hideki Tamura,et al.  NMDA-Dependent Proteolysis of Presynaptic Adhesion Molecule L1 in the Hippocampus by Neuropsin , 2003, The Journal of Neuroscience.

[38]  T. Kishi,et al.  Human kallikrein 8: immunoassay development and identification in tissue extracts and biological fluids. , 2003, Clinical Chemistry.

[39]  D. Grönemeyer,et al.  Assessment of clinically silent atherosclerotic disease and established and novel risk factors for predicting myocardial infarction and cardiac death in healthy middle-aged subjects: rationale and design of the Heinz Nixdorf RECALL Study. Risk Factors, Evaluation of Coronary Calcium and Lifestyle. , 2002, American heart journal.

[40]  J. Morris,et al.  Current concepts in mild cognitive impairment. , 2001, Archives of neurology.

[41]  G. Yousef,et al.  Expression of the kallikrein gene family in normal and Alzheimer's disease brain , 2001, Neuroreport.

[42]  G. Yousef,et al.  The new human tissue kallikrein gene family: structure, function, and association to disease. , 2001, Endocrine reviews.

[43]  K. Shulman.  Clock‐drawing: is it the ideal cognitive screening test? , 2000, International journal of geriatric psychiatry.

[44]  M. Shibata,et al.  Characterization of Recombinant and Brain Neuropsin, a Plasticity-related Serine Protease* , 1998, The Journal of Biological Chemistry.

[45]  J. Stroop.  Studies of interference in serial verbal reactions. , 1992 .